ArticleThe American journal of tropical medicine and hygiene2016
Implications of Plasmodium vivax Biology for Control, Elimination, and Research.
Article in The American journal of tropical medicine and hygiene, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it, 77 citations in OpenAlex.
- Plasmodium vivax epidemiology in Ethiopia 2000-2020: A systematic review and meta-analysis.PLoS neglected tropical diseases · 2021Pooled it
- Associations between weather and Plasmodium vivax malaria in an Amazonian elimination setting: a distributed lag analysis from 2017 to 2024.Malaria journal · 2026Article
- Extreme Genetic Diversity and Signatures of Balancing Selection in Plasmodium vivax Blood-Stage Antigens.The Journal of infectious diseases · 2026Article
- Efficacy of artemether lumefantrine vs chloroquine for the treatment of Plasmodium Vivax infection in Pakistan.Scientific reports · 2026Observational
- Malaria Diagnosis Status in Republic of Korea, 2021-2025.Public health weekly report · 2026Article
- Vector Surveillance in Malaria Risk Areas in 2025.Public health weekly report · 2026Article
- Extreme weather events and vector-borne diseases: Quantifying the epidemiological effect of Hurricane Julia on malaria transmission in Colombia.PLOS global public health · 2026Article
- Molecular Profiles of Antimalarial Drug Resistance inMicroorganisms · 2025Article
- Current and future temperature suitability for autochthonous transmission of malaria in Canada.International journal of health geographics · 2025Article
- A tale of two parasites: a glimpse into the RNA methylome of patient-derived Plasmodium falciparum and Plasmodium vivax isolates.Malaria journal · 2025Article
- Asymptomatic malaria reservoirs are the last challenge in the elimination in Cambodia.Malaria journal · 2025Article
- Modeling and investigating malaria P. Falciparum and P. Vivax infections: Application to Djibouti data.Infectious Disease Modelling · 2024Article
- Associations between weather andmedRxiv : the preprint server for health sciences · 2024Article
- Transmission-blocking activities of artesunate, chloroquine, and methylene blue onAntimicrobial agents and chemotherapy · 2024Article
- Population genomic evidence of structured and connectedEcology and evolution · 2024Article
- Naturally Acquired Transmission-Blocking Immunity Against Different Strains of Plasmodium vivax in a Malaria-Endemic Area in Thailand.The Journal of infectious diseases · 2024Article
- Plasmodium vivax Prevalence in Semiarid Region of Northern Kenya, 2019.Emerging infectious diseases · 2023Article
- An active and targeted survey reveals asymptomatic malaria infections among high-risk populations in Mondulkiri, Cambodia.Malaria journal · 2023Article
- Infectivity of symptomaticCurrent research in parasitology & vector-borne diseases · 2023Article
- Plasmodium vivax: the potential obstacles it presents to malaria elimination and eradication.Tropical diseases, travel medicine and vaccines · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 8 institutions in 7 countries.
Funding
Abstract
This paper summarizes our current understanding of the biology of Plasmodium vivax, how it differs from Plasmodium falciparum, and how these differences explain the need for P. vivax-tailored interventions. The article further pinpoints knowledge gaps where investments in research are needed to help identify and develop such specific interventions. The principal obstacles to reduce and eventually eliminate P. vivax reside in 1) its higher vectorial capacity compared with P. falciparum due to its ability to develop at lower temperature and over a shorter sporogonic cycle in the vector, allowing transmission in temperate zones and making it less sensitive to vector control measures that are otherwise effective on P. falciparum; 2) the presence of dormant liver forms (hypnozoites), sustaining multiple relapsing episodes from a single infectious bite that cannot be diagnosed and are not susceptible to any available antimalarial except primaquine, with routine deployment restricted by toxicity; 3) low parasite densities, which are difficult to detect with current diagnostics leading to missed diagnoses and delayed treatments (and protracted transmission), coupled with 4) transmission stages (gametocytes) occurring early in acute infections, before infection is diagnosed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.